Looks like NSB are looking to out-licence their product post Phase 1 clinical trials. This has it's own pros and cons. For those not familiar with in/out licencing process the below link will help explain.
https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/what-is-in-licensing/
